Article information
Full text is only aviable in PDF
BIBLIOGRAFIA
[1.]
Y. Ariyoshi, et al.
Therapeutic significance of neuron-specific enolase (NSE) in lung cancer.
Proc Am Assoc Clio Oncol, 5 (1986),
[2.]
H.H. Berendsen, L. Leij, S. Poppema, P. Postmus, A. Boes, H.J. Sluiter.
The H. Clinical charactherization of non-small-cell lung cancer tumors showing neuroendocrine differentiation features.
J Clin Oncol, 7 (1989), pp. 1614-1620
[3.]
G. Buccheri, D. Ferrigno, A. Rosso, F. Vola.
Further evidence in favour of chemotherapy for inoperable non-small cell lung cancer.
Lung Cancer, 6 (1990), pp. 87-98
[4.]
G. Buccheri, D. Ferrigno.
Prognostic factors in lung cancer: tables and comments.
Eur Respir J, 7 (1994), pp. 1350-1364
[5.]
J. Carles, et al.
Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer.
Lung Cancer, 10 (1993), pp. 209-219
[7.]
T. Le Chevalier, et al.
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer results of a European Multicenter Trial including 612 patients.
J Clin Oncol, 12 (1994), pp. 360-367
[8.]
M. Diez, et al.
Value of serum neuron-specific enolase in nons mall cell lung cancer.
Oncology, 50 (1993), pp. 127-131
[9.]
A. Gazdar.
Expression of neuroendocrine markers in non-SCLC (NSCLC) tumors and cell lines possible therapeutic implications,
[11.]
S.L. Graziano, et al.
The use of neuroendocrine immunope-roxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer.
J Clin Oncol, 7 (1989), pp. 1398-1406
[12.]
S.L. Graziano, et al.
The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and stage II non-small cell lung cancer.
Cancer Res, 54 (1994), pp. 2908-2913
[13.]
F.R. Hirsch.
The clinical implication of neuroendocrine markers in non-small cell lung cancer.
Lung Cancer, 11 (1994), pp. 201-202
[14.]
F.R. Hirsch, B.G. Skov.
Neuroendocrine characteristics in bronchogenic adenocarcinoma and its clinical relevance.
Lung Cancer, 9 (1993), pp. 89-96
[15.]
B.E. Johnson.
Biologic and molecular prognostic factors. Impact on treatment of patients with non-small cell lung cancer.
Chest, 107 (1995), pp. 287s-290s
[16.]
S.D.J.M. Kanters, J.-W.J. Lammers, E.E. Voest.
Molecular and biological factors in the prognosis of non-small cell lung cancer.
Eur Respir J, 8 (1995), pp. 1389-1397
[17.]
R.E. Kibbelaar, et al.
Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma.
Eur J Cancer, 27 (1991), pp. 431-435
[18.]
P. Kiriakogiani-Psaropoulou, et al.
The value of neuroendocrine markers in non-small cell lung cancer a comparative immunohistopathologic study.
Lung Cancer, 11 (1994), pp. 353-364
[19.]
H.B. Kwa, R.J.A.M. Michalides, J.H. Dijkman, W.J. Mooi.
The prognostic value of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer.
Lung Cancer, 14 (1996), pp. 207-217
[20.]
R.I. Linnoila, S. Piantadosi, J.C. Ruckdeschel.
Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experinence.
Chest, 106 (1994), pp. 367s-371s
[21.]
W. Mooi, S. Wagenaar, D. Schol, J. Hilgers.
Monoclonal antibody 123C3 in lung tumour classification: immunohistology of 358 resected lung tumours.
Mol Cell Probes, 2 (1988), pp. 31-37
[23.]
J. Mulshine, D. Ihde, R.I. Linnoila.
Preliminary report of a prospective mal of neuroendocrine marker analysis and in vitro drug sensivity testing in patients with non-small ell lung cancer.
Proc Am Assoc Clin Oncol, 6 (1987), pp. 713
[24.]
M.H. Neal, K. Kosinski, P. Cohen, J.M. Orenstein.
Atypical endocrine tumors of the lung: a histologic, ultrastructural and clinical study of 19 cases.
Human Pathol, 17 (1986), pp. 1264-1277
[25.]
G.L. Nicolson.
Tumor cell Instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression.
Cancer Res, 47 (1987), pp. 1473-1487
[26.]
J.-L. Pujol, et al.
Neural cell adhesion molecule and prognosis of surgically resected lung cancer.
Am Rev Respir Dis, 148 (1993), pp. 1071-1075
[27.]
J. Ruckdeschel.
The impact of neuroendocrine and epithelial differentation on recurrence and survival in patients with lung cancer.
Lung Cancer, 7 (1991), pp. 204
[28.]
J.T. Schleusener, et al.
Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma.
Cancer, 77 (1996), pp. 1284-1291
[29.]
M.N. Sheppard.
Neuroendocrine differentiation in lung tumours.
Thorax, 46 (1991), pp. 843-850
[30.]
B.G. Skov, J.B. Sørensen, F.R. Hirsch, L.I. Larsson, H.H. Hansen.
Prognostic Impact of histologic demonstration of chromogranin A and neuron specific enolase in pulmonary adenocarcinoma.
Ann Oncol, 2 (1991), pp. 355-360
[31.]
J.B. Sørensen.
Impact of prognostic factors on endpoints for climcal studies.
Lung cancer, 11 (1994), pp. s45-s54
[32.]
R. Sotto-Mayor.
Clinica e terapêutica dos tumores neuroendócrinos do pulmão.
Rev Port Pneumol, 1 (1995), pp. 519-539
[33.]
R.L. Souhami.
Neuroendocrine phenotype, chemosensitivity and prognosis in adenocarcinoma of the lung (Editorial).
Ann Oncol, 2 (1991), pp. 323-324
[34.]
V. Sundarensan, J.G. Reeve, S. Stenning, Stewarts, N.M. Bleehen.
Neuroendocnne differentiatton and clinical behaviour in non-small cell lung tumours.
Br J Cancer, 64 (1991), pp. 333-338
[36.]
The World Health Organization Histological Typing of Lung Tumors.
Am J Clin Pathol, 77 (1982), pp. 123-136
[38.]
N. van Zandwijk, et al.
Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer.
Sem Oncol, 19 (1992), pp. 37-43
Special content about COVID-19
- Issue 4—Impact of air pollution on COVID-19 mortality and morbidity: An epidemiological and mechanistic review
- Hyperoxemia in invasively ventilated COVID–19 patients–Insights from the PRoVENT–COVID study
- Association between respiratory distress time and invasive mechanical ventilation in COVID-19 patients: A multicentre regional cohort study
- Assisted mobilisation in critical patients with COVID-19
Open access
This work is licensed under a Creative Commons Attribution 4.0 International License.
Publish in
Pulmonology
Pulmonology
- Home
- All contents
- Publish your article
- About the journal
- Metrics
- Open access
Article options